BioNotebook: Incyte, Agenus sign $410m immuno-oncology pact; plus six more deals
This article was originally published in Scrip
Incyte will pay Agenus $60m up front and $350m in development, regulatory and commercial milestone fees to license the Retrocyte Display antibody discovery platform for the development of novel immunotherapies. The upfront fee is comprised of a $25m technology and program access fee as well as a $35m equity investment at $4.51 per share.
You may also be interested in...
Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.